Sustained-release fampridine for multiple sclerosis

Expert Opinion on Investigational Drugs

Volumn 18, Issue 7, 2009, Pages 1013-1024

  Bever Jr , Christopher T ^a   Judge IV, Susan ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

4 aminopyridine; Ambulation; Clinical trials; Demyelination; Fampridine; Multiple sclerosis; Paresthesias; Potassium channels; Seizure; Weakness

Indexed keywords

4 AMINOPYRIDINE; 4 AMINOPYRIDINE DERIVATIVE; AMINOPYRIDINE; AMINOPYRIDINE DERIVATIVE; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; ION CHANNEL; MITOXANTRONE; NATALIZUMAB; NEUROTRANSMITTER; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

ACTION POTENTIAL; ASTHENIA; BACKACHE; BALANCE DISORDER; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISORIENTATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; EATON LAMBERT SYNDROME; FALLING; FATIGUE; FOOD AND DRUG ADMINISTRATION; GUILLAIN BARRE SYNDROME; HUMAN; INSOMNIA; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELINATED NERVE; NAUSEA; NERVE INJURY; NEUROPATHY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; SIDE EFFECT; SPINAL CORD INJURY; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; URINARY TRACT INFECTION; WALKING SPEED;

4-AMINOPYRIDINE; ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DELAYED-ACTION PREPARATIONS; HUMANS; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS;

EID: 67650465866     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903002082     Document Type: Review

References (57)

1. Anonymous. Business wire: Acorda Therapeutics submits new drug application for Fampridine SR for improvement of walking ability in people with multiple sclerosis. Wall Street Jounal Online, 2 February 2009. Available from: http://online.wsj.com/article/ PR-CO-20090202-901621.html? mod = wsjcrmain [Cited 25 Feb 2009]
2. Compston A, Confavreux C. The distribution of multiple sclerosis. In: Compston A, editor, McAlpine's multiple sclerosis. 4th edition. Philadelphia, PA: Churchill Livingstone; 2005. p. 71-111
3. Burton JM, Bell CM, Walker SE, O'Connor PW. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008;71:1833-4
4. van Diemen HAM, Polman CH, Koetsier JC, et al. 4-aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16:195-204
5. Bever CT, Young D, Anderson PA, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double blind, concentration controlled crossover trial. Neurology 1994;44:1054-9
6. Bever CT, Young D, Tierney D, et al. The pharmacokinetics and tolerability of a slow-release formulation of 4-aminopyridine in multiple sclerosis. Neurology 1995;45(Suppl):A351
7. Cohen R. 4-Aminopyridine. In: Pharmacy Compounding Advisory Committee transcript, 6 May 1999, 165-261. Available from: www.fda.gov/ohrms/dockets/ac/ 99/ transcpt/3513t1.rtf [Cited 25 Feb 2009]
8. Available from: www.acorda.com [Cited 23 Feb 2009]
9. Frohman E, Racke M, Raine C. Multiple sclerosis: the plaque and its pathogenesis. N Engl J Med 2006;354:942-55 • This is an up-to-date and concise review of MS lesion pathogenesis.
10. Confavreux C, Compston A. The natural history of multiple sclerosis. In: Compston A, editor. McAlpine's multiple sclerosis. 4th edition. Philadelphia, PA: Churchill Livingstone; 2005. p. 183-269
11. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-7
12. Mcdonald I, Compston A. The symptoms and signs of multiple sclerosis. In: Compston A, editor, McAlpine's Multiple Sclerosis: Fourth Edition. Churchill Livingstone Elsevier, Philadelphia, PA, USA; 2005. p. 287-346
13. Noseworthy J, Miller D, Compston A. The treatment of symptoms in multiple sclerosis and the role of rehabilitation. In: Compston A, editor, McAlpine's Multiple Sclerosis: Fourth Edition, Churchill Livingstone Elsevier, Philadelphia, PA, USA; 2005. p. 701-25 • References 10, 11 and 12 are three excellent review chapters from the fourth edition of one of the classic reference texts for multiple sclerosis.
14. Available from: www.sanofiaventis.com; [Accessed 22 February 2008]
15. Judge SIV, Bever CT. Potssium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharm Ther 2006;111:224-59
16. DeGrazio JW, Besser JF, Decino TJ, et al. Use of 4-aminoppyridine to protect ripening corn from blackbirds. J Wildl Mgmt 1971;35:565-9
17. Judge SIV, Yeh JZ, Goolsby JE, et al. Determinants of 4-aminopyridine sensitivity in a human brain Kv1.4 K + channel: Phenylalanine substitutions in leucine heptad repeat region stabilize channel closed state. Mol Pharm 2002;61:913-20
18. Judge SIV, Monteiro MJ, Yeh JZ, Bever CT. Inactivation gating and 4-AP sensitivity in human brain Kv1.4 potassium channel. Brain Res 1999;831:43-54
19. Lai HC, Jan LY. The distribution and targeting of neuronal voltage-gated ion channels. Nat Rev Neurosci 2006;7:548-62
20. Rutecki PA, Labeda FJ, Johnson D. 4-aminopyridine produces epileptiform activity in the hippocampus and enhances synaptic excitation and inhibition. J Neurophysiol 1987;57:1911-24
21. Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-84 • A classic paper on the physiological mechanism of 4-aminopyridine.
22. Lemeignan M, Lechat P. Sur l'action anticurare des aminopyridines. C R Acad Sci Paris Serie D 1967;264:169-72
23. Agoston S, Salt PJ, Erdmann W, et al. Antagonism of ketamine-diazepam anesthesia by 4-aminopyridine in human voluteers. Br J Anesth 1980;52:367-70
24. Molgo J, Lemeignan M, Lechat P. Effects of 4-aminopyridine at the frog neuromuscular junction. J Pharmacol Exp Ther 1977;203:653-63
25. Heuser JE, Reese TS, Dennis MJ, et al. Synatpic vescicle exocytosis captured by quick freezing and correlated with quantal transmitter release. J Cell Biol 1979;81:275-300
26. Glover WE. The aminopyridines. Gen Pharmacol 1982;13:259-85
27. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981;31:265-71
28. Smith JP, Waxman SG. The conduction properties of demyelinated and remyelinated axons. In: Waxman SG, editor, Multiple Sclerosis as a Neuronal Disease, Elsevier Academic Press, Amsterdam; 2005. p. 85-100
29. Rasband MN. Potassium channel organization of myelinated and demyelinated axons. In: Waxman SG, editor, Multiple Sclerosis as a Neuronal Disease, Elsevier Academic Press, Amsterdam; 2005. p. 57-67 • References 27 and 28 are excellent chapters among many from a new reference text that explores a new approach to conceptualizing multiple sclerosis.
30. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989;22:47-52 • One of the key studies providing the rationale for the use of 4-aminopyridine in patients with spinal cord injury.
31. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian fibers. J Physiol 1981;313:301-15 • A classic paper on the physiology of 4-aminopyridine in demyelinated nerve fibers.
32. Evenhuis J, Agoston S, Salt PJ, et al. Pharmacokinetics of 4-aminopyridine in human volunteers: a preliminary study using a new GLC method for its estimation. Br J Anesth 1981;53:567-70
33. Hayes KC, Katz MA, Devane JG, et al. Pharmacokinetics of an immediate-release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;31:379-85
34. Uges DRA, Sohn YJ, Greijdanus B, et al. 4-aminopyridine kinetics. Clin Pharmacol Ther 1982;31:587-93
35. Blight AR, Henney HR. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. Clin Ther 2009;31:328-35
36. Segal JL, Hayes KC, Brunnemann SR, et al. Absorption characteristics and tolerability of a slow-release formulation of 4-aminopyridine in patients with chronic spinal cord injury. J Clin Pharmacol 2000;40:402-9
37. Jones HE, Heron JR, Foster DH, et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983;60:353-62
38. Stefoski D, Davis FA, Faut M, Schauf CL. 4-aminopyridine in patients with multiple sclerosis. Ann Neurol 1987;27:71-5
39. Davis FA, Stefoski D, Schauf CL. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990;27:186-92
40. Stefoski D, Davis FA, Fitzsimmons WE, et al. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991;41:1344-8
41. van Diemen HAM, Polman CH, van Dongen MM, et al. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993;116:220-6
42. van Diemen HAM, Polman CH, van Dongen MM, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, crossover study. Ann Neurol 1992;32:123-30
43. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52 • One of the most cited papers in the field of multiple sclerosis research: the original description of what is still the most widely used and accepted rating scale for disability in MS.
44. Polman CH, Bertelsmann FW, de Waal, et al. 4-aminopyridine in superior to 3,4 diaminopyridine in the treatment of multiple sclerosis. Arch Neurol 1994;51:1136-9
45. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis: Long-term efficacy and safety. Arch Neurol 1994;51:292-6
46. Smits RCF, Emmen HH, Bertelsmann FW, et al. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994;44:1701-5
47. Bever CT, Katz E, Tierney D, Johnson KP. Experience with slow release 4-aminopyridine in multiple sclerosis patients: long term tolerability and safety. J Neuroimmunol 1995;1(Suppl):58
48. Schwid SR, Petrie MD, McDermott MP, et al. Quantitative assessment of sustained release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 1997;48:817-21
49. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose ranging study. Mult Scler 2007;13:357-68
50. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
51. Kryscio RJ. Fampridine for MS responders: clinically relevant or hypothesis generating? Neurology 2008;71:1130-1
52. Goodman AD, Brown T, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial. Lancet 2009;373:732-8
53. Goodman AD, Schwid S, Brown T, et al. Sustained-release fampridine consistently improves walking speed and leg strength in multiple sclerosis: a phase 3 trial. World Congress of Treatment and Research in Multiple Sclerosis, Montreal, 2008, Program, Poster session 3 - Late Breaking News, P909
54. Anonymous. Betaseron. In: Physicians Desk Reference. PDR Staff, editor, 2007, Thompson Health Care Inc., Montvale, NJ, 767-771
55. Hayes KC. Fampridine-SR in multiple sclerosis and spinal cord injury. Expert Rev Neurother 2007;7:1-9 • An excellent review of both the background for and use of 4-aminopyrdine in spinal cord injury and multiple sclerosis.
56. Rucker JC. Current treatment of nystagmus. Curr Treat Options Neurol 2005;7:69-77
57. Judge SIV, Lee JM, Bever CT, Hoffman PM. Voltage-gated potassium channels in multiple sclerosis: overview and new implications for treatment of central nervous system inflammation and degeneration. J Rehab Res Dev 2006;43:111-22